Title |
VS411 Reduced Immune Activation and HIV-1 RNA Levels in 28 Days: Randomized Proof-of-Concept Study for AntiViral-HyperActivation Limiting Therapeutics
|
---|---|
Published in |
PLOS ONE, October 2012
|
DOI | 10.1371/journal.pone.0047485 |
Pubmed ID | |
Authors |
Franco Lori, Davide De Forni, Elly Katabira, Denis Baev, Renato Maserati, Sandra A. Calarota, Pedro Cahn, Marco Testori, Aza Rakhmanova, Michael R. Stevens |
Abstract |
A new class of antiretrovirals, AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs), has been proposed as a disease-modifying therapy to both reduce Human Immunodeficiency Virus Type 1 (HIV-1) RNA levels and the excessive immune activation now recognized as the major driver of not only the continual loss of CD4(+) T cells and progression to Acquired Immunodeficiency Syndrome (AIDS), but also of the emergence of both AIDS-defining and non-AIDS events that negatively impact upon morbidity and mortality despite successful (ie, fully suppressive) therapy. VS411, the first-in-class AV-HALT, combined low-dose, slow-release didanosine with low-dose hydroxycarbamide to accomplish both objectives with a favorable toxicity profile during short-term administration. Five dose combinations were administered as VS411 to test the AV-HALT Proof-of-Concept in HIV-1-infected subjects. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 3% |
South Africa | 1 | 3% |
Unknown | 33 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 8 | 23% |
Student > Bachelor | 5 | 14% |
Student > Master | 5 | 14% |
Student > Ph. D. Student | 4 | 11% |
Student > Postgraduate | 3 | 9% |
Other | 4 | 11% |
Unknown | 6 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 20% |
Agricultural and Biological Sciences | 7 | 20% |
Immunology and Microbiology | 5 | 14% |
Nursing and Health Professions | 2 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
Other | 5 | 14% |
Unknown | 7 | 20% |